Home
[an error occurred while processing this directive]
Quality survey Health benefits Safety Reading labels Ask the supplier Standards & regulations



Editorials





Testing news
Search
Links
Glossary
Glossary
Ask the expert
Bookstore
Sponsorship
Contact us
Disclaimer
Privacy policy
Sponsorship
 

Cautions and potential hazards

FDA Warns Consumers Not to Use the Dietary Supplement LipoKinetix
Bethesda MD, 19 November 2001

The Food and Drug Administration (FDA) is warning consumers to immediately stop use of the product LipoKinetix, marketed as a dietary supplement by Syntrax Innovations, Inc. LipoKinetix has been implicated in a number of serious liver injuries. FDA has received multiple reports of persons who developed liver injury or liver failure while using LipoKinetix.

LipoKinetix is marketed for weight loss. It contains the ingredients norephedrine (also known as phenylpropanolamine or PPA), caffeine, yohimbine, diiodothyronine, and sodium usniate. The injuries reported to FDA occurred in persons between 20 and 32 years of age. No apparent cause of liver injury was identified in these reports other than use of LipoKinetix. Liver injury developed between 2 weeks and 3 months of LipoKinetix use.

FDA urges consumers to discontinue use of LipoKinetix and consult their physician if they are experiencing symptoms possibly associated with this product, particularly nausea, weakness or fatigue, abdominal pain, or any change in skin color. Consumers or health care professionals who are aware of adverse effects after the use of this or other dietary supplement products can report the adverse event to FDA's MedWatch adverse event and product problem hot line at 1-800-FDA-1088.

Excerpts from the FDA's accompanying Letter to Health Care Professionals

LipoKinetix has been implicated in several cases of serious liver injury. The FDA has received reports of at least six persons who developed acute hepatitis and/or liver failure while using LipoKinetix. The injuries reported to FDA occurred in persons between 20 and 32 years of age. No other cause for liver disease was identified. In all cases, no preexisting medical condition that would predispose the consumer to liver injury was identified. Onset of liver injury was observed between 2 weeks and 3 months of starting LipoKinetix.

LipoKinetix has been promoted for weight loss by 'mimicking exercise' and supporting 'an increased metabolic rate'.end of story

 

 

 

   
[an error occurred while processing this directive]
Health benefits Safety Reading labels Ask the supplier Standards & regulations Contact us

(c) Copyright 1999-2003 Dietary Supplement Quality Initiative. For permission to reprint, please contact our editor.